DiaCarta
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3857 Breakwater Ave, Hayward, California...Phone Number
(510) 735-8636Website
www.diacarta.comRevenue
$28.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About DiaCarta
DiaCarta is a leading precision diagnostic company specializing in translational genomics and personalized diagnostics, particularly in cancer gene mutation detection. Their innovative technologies, including XNA and isobDNA, enable sensitive and accurate detection of genetic alterations, positioning them as a leader in the precision diagnostic industry. The company offers a comprehensive suite of diagnostic products and services for oncology and infectious diseases, catering to healthcare providers and patients worldwide. With a commitment to advancing precision medicine, DiaCarta collaborates with pharmaceutical and biopharmaceutical companies, as well as clinicians, to enhance patient care.Explore more
DiaCarta Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DiaCarta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when DiaCarta launches new products
Congratulate Masked Content for being promoted to Masked Content at DiaCarta
Check if DiaCarta has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on DiaCarta recently announced quarterly report
DiaCarta, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if DiaCarta had a recent Job posting/layoffs
Check out if DiaCarta is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once DiaCarta has new funding data
Recommended Actions
Reach out to Masked Content who joined DiaCarta as Masked Content
Find 3 more new buyers
Compare Similar Companies to DiaCarta
Compare insights from companies similar to DiaCarta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DiaCarta is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DiaCarta is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DiaCarta.
DiaCarta financials insights
Gather financial insights about DiaCarta, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$8M
2018
Series B
$45M
DiaCarta Tech Stack
A closer look at the technologies used by DiaCarta
See more technologies
Most Recent Scoops
Project
Product Development, Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Partnership, Engineering, Clinical Systems
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Event
will be attending the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo conference as an exhibitor. The event will occur from July 24 to July 28, 2022.
Funding
DiaCarta News & Media
DiaCarta Reports Positive Clinical Trial Data For Its Blood Based Test to Triage FIT-Positive Patients Enrolled in CRC Screening Programs
PLEASANTON, Calif., Jan. 3, 2025 /PRNewswire/ -- DiaCarta Inc., a precision molecular diagnostic company, has announced the publication of its prospective clinical trial data on its blood-based test for triaging FIT (fecal immunochemical test)-positive patients in colorectal cancer (CRC)...DiaCarta Enters Contract with the VA Health Care System (San Francisco) for VEXAS Syndrome Testing
PLEASANTON, Calif., Oct. 3, 2024 /PRNewswire/ -- DiaCarta, a leading molecular diagnostic company specializing in oncology and infectious disease tests, announces today that it has entered into a diagnostic testing service contract with the Department of Veterans Affairs San Francisco VA...DiaCarta Helps Communities Scale Up Their MPOX Testing Efforts with Its Simple, Reliable, and FDA-EUA-Approved MPOX Testing Kits
PLEASANTON, Calif., Sept. 3, 2024 /PRNewswire/ -- DiaCarta, Inc., an experienced in-vitro diagnostics (IVD) company that provided COVID-19 testing kits during the global pandemic, has expanded its focus to mpox detection and the detection of other infectious diseases. As the demand for...DiaCarta and Capstone Health Alliance Collaborate to Bring Revolutionary Diagnostic Tests to Enhance Patient Care
ASHEVILLE, N.C., June 26, 2024 /PRNewswire/ -- DiaCarta, Inc. ("DiaCarta"), a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DiaCarta
Sign Up For FreeTo access detailed company insights
DiaCarta is a leading precision diagnostic company specializing in translational genomics and personalized diagnostics, particularly in cancer gene mutation detection. Their innovative technologies, including XNA and isobDNA, enable sensitive and accurate detection of genetic alterations, positioning them as a leader in the precision diagnostic ind... Read More
